haematological cancers

News

AACR 2025: Quintet of investigational oncological drugs puts...

Ascentage Pharma, specialising in haematological malignancies, has presented results from five preclinical studies at AACR 2025.

Oncology

Driving innovation in multiple myeloma to improve the patien...

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies.1

News

ESC26: Isomab safety evidence on blood vessel growth for CAD

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks